Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupDermatologic OncologyT-Cell and NK-Cell NeoplasmsDiseaseNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Cutaneous, UnspecifiedNHL, T-Cell Type, Cutaneous Primary, CD30-PositiveNHL, T-Cell Type, Mycosis FungoidesNHL, T-Cell Type, Peripheral, UnspecifiedNHL, T-Cell Type, Sézary SyndromeT-Cell Prolymphocyte LeukemiaSubgroupCD30+JAK2 rearrangementICD10C84.0C84.1C84.4C84.8C86.5C86.6C91.6-MeSHImmunoblastic LymphadenopathyLeukemia, Prolymphocytic, T-CellLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralMycosis FungoidesSezary SyndromeSequenceMAVORIC: MOGA1, CTCL, C1 (PID1397) -|- C2-12 (PID1398)ChemotherapyChemo-substanceBrentuximab vedotinDoxorubicin pegylated liposomalGemcitabineMogamulizumabRuxolitinibChemo-substanceBrentuximab vedotinDoxorubicin pegylated liposomalGemcitabineMogamulizumabRuxolitinibChemo-substanceBrentuximab vedotinDoxorubicin pegylated liposomalGemcitabineMogamulizumabRuxolitinibChemo-substanceBrentuximab vedotinDoxorubicin pegylated liposomalGemcitabineMogamulizumabRuxolitinibNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronParacetamolPyridoxineSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronParacetamolPyridoxineSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronParacetamolPyridoxineSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronParacetamolPyridoxineNo. Substances234Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationRelapse therapySecond lineseveral possibleThird line Therapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlAnemia Hb below 10g/dlAstheniaDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHand-Foot SyndromeHypertensionIncrease AminotransferasesInfusion ReactionLeukopeniaMucositisNauseaNeuropathyNeutropeniaPneumoniaPruritusPyrexiaSepsisThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorDuvic MKim YHMoskowitz AJ Prince HMQuereux GDiseasefortgeschrittenes, kutanes T-Zell-Lymphomkutanes T-Zell-Lymphom, CD30+, mindestens eine Vortherapie, ECOG 0-2Peripheres T- oder NK-Zell Lymphom, kutanes T-Zell Lymphom (Stadium IB oder höher), T-PLLrefraktäres oder rezidivierendes kutanes T-Zell-Lymphom, 2 oder mehr Vorbehandlungen, ECOG 0-2refraktäres oder rezidivierendes kutanes T-Zell-Lymphom, eine oder mehr Vorbehandlungen, ECOG 0-1OriginDepartment of Dermatology, The University of Texas M. D. Anderson Cancer Center, HoustonDepartments of Dermatology, Centre Hospitalier Universitaire, Nantes, FranceDivision of Cancer Medicine, Peter MacCallum Cancer Centre, The University of Melbourne, ALCANZAMemorial Sloan-Kettering Cancer Center, New York, NYStanford University, Stanford, CA, USA, MAVORICProtocols in Revision 6 protocols foundProtocols under revision.Brentuximab Vedotin 1.8, cutaneous T-cell lymphoma (PID1389 V1.0)Gemcitabine 1000, cutaneous T-cell lymphoma (PID1388 V1.0)Mogamulizumab 1, cutaneous T-cell lymphoma, cycle 1 (PID1397 V1.0)Mogamulizumab 1, cutaneous T-cell lymphoma, cycle 2-12 (PID1398 V1.0)Pegylated Doxorubicin Liposomal 40, cutaneous T-cell lymphoma (PID1387 V1.0)Ruxolitinib 20, T-Cell Lymphoma / T-Cell Prolymphocyte Leukemia (PID2478 V1.0)
